Your browser doesn't support javascript.
loading
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Schmid, Peter; Sablin, Marie-Paule; Bergh, Jonas; Im, Seock-Ah; Lu, Yen-Shen; Martínez, Noelia; Neven, Patrick; Lee, Keun Seok; Morales, Serafín; Pérez-Fidalgo, J Alejandro; Adamson, Douglas; Gonçalves, Anthony; Prat, Aleix; Jerusalem, Guy; Schlieker, Laura; Espadero, Rosa-Maria; Bogenrieder, Thomas; Huang, Dennis Chin-Lun; Crown, John; Cortés, Javier.
Afiliação
  • Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. p.schmid@qmul.ac.uk.
  • Sablin MP; Department of Drug Development and Innovation, Institut Curie, Paris, France.
  • Bergh J; Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden.
  • Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Lu YS; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Martínez N; Department of Oncology, Ramon y Cajal University Hospital, Madrid, Spain.
  • Neven P; Department of Oncology, UZ Leuven, Campus Gasthuisberg, Leuven, Belgium.
  • Lee KS; Department of Internal Medicine, National Cancer Center, Goyang, South Korea.
  • Morales S; Department of Medical Oncology, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain.
  • Pérez-Fidalgo JA; Medical Oncology Unit, Hospital Clinico Universitario Valencia, Biomedical Research Institute INCLIVA, CIBERONC, Valencia, Spain.
  • Adamson D; Department of Medical Oncology, Ninewells Hospital, Tayside Cancer Centre, Dundee, UK.
  • Gonçalves A; Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille University, CRCM, CNRS, INSERM, Marseille, France.
  • Prat A; Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Jerusalem G; Department of Medical Oncology, Centre Hospitalier Universitaire de Liège, and Liège University, Liège, Belgium.
  • Schlieker L; External statistician on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG., Staburo GmbH & Co. KG., Munich, Germany.
  • Espadero RM; Medical Department (Clinical Operations), Boehringer Ingelheim España S.A, Barcelona, Spain.
  • Bogenrieder T; Medical Department, Boehringer Ingelheim, RCV, Vienna, Austria.
  • Huang DC; Present Address: Amal Therapeutics SA, Geneva, Switzerland.
  • Crown J; Medical Department, Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan.
  • Cortés J; Present Address: MSD Taiwan, Taipei, Taiwan.
Breast Cancer Res ; 23(1): 8, 2021 01 15.
Article em En | MEDLINE | ID: mdl-33451345
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article